Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May;21(3):204-210.
doi: 10.7861/clinmed.2021-0045.

Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations for non-diabetes specialists on the use of sodium glucose co-transporter 2 inhibitors in people with type 2 diabetes (January 2021)

Umesh Dashora  1 , Robert Gregory  2 , Peter Winocour  3 , Ketan Dhatariya  4 , Susannah Rowles  5 , Andrew Macklin  6 , Gerry Rayman  7 , Dinesh Nagi  8 , Katie Whitehead  9 , Hannah Beba  10 , Parijat De  11 , Dipesh C Patel  12 ; ABCD executive committee and Diabetes UK
Affiliations

Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations for non-diabetes specialists on the use of sodium glucose co-transporter 2 inhibitors in people with type 2 diabetes (January 2021)

Umesh Dashora et al. Clin Med (Lond). 2021 May.

Abstract

Sodium glucose co-transporter 2 (SGLT2) inhibitors are now an established class of medications for the treatment of type 2 diabetes (T2D), no longer reserved for use by specialists in diabetes. They are being used increasingly for their cardiac and renal benefits by primary care, cardiology and renal teams for indications in parallel with diabetes care as part of holistic management. This guidance provides essential information on SGLT therapy, including the main advantages and the important risks of which healthcare professionals should be aware.

Keywords: ABCD; Diabetes UK; SGLT2 inhibitors; non-diabetes specialists; type 2 diabetes.

PubMed Disclaimer

Figures

Fig 1.
Fig 1.
Cardiovascular and renal effects of sodium glucose co-transporter 2 inhibitors. SBP = systolic blood pressure; SGLT2 = sodium glucose co-transporter 2.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Buse JB, Wexler DJ, Tsapas A, et al. . 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2020;43:487–93. - PMC - PubMed
    1. American Diabetes Association . 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. Diabetes Care 2020;43:S14. - PubMed
    1. Dhatariya KK, Glaser NS, Codner E, Umpierrez GE. Diabetic ketoacidosis. Nat Rev Dis Primers 2020;6:40. - PubMed
    1. World Health Organization . Diabetes: Data and statistics. WHO. www.euro.who.int/en/health-topics/noncommunicable-diseases/diabetes/data... [Accessed 14 January 2020].
    1. Afkarian M, Sachs M, Kestenbaum B, et al. . Kidney disease and increased mortality risk. Journal of American Society of Nephrology 2013,24:302–8. - PMC - PubMed